Evotec achieves milestone with Cardioxyl Pharmaceuticals - as compound enters the clinic


Hamburg, Germany/ Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC), a leading provider in the discovery and development of novel small molecule drugs, today announced that the company has achieved an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, that has successfully moved into clinical testing. This milestone has triggered a success payment from Cardioxyl Pharmaceuticals to Evotec.

Evotec has been providing medicinal chemistry support to Cardioxyl for over three years.  During this time the compound, CXL-1020, was developed through lead optimization and pre-clinical development activities, and has now progressed to Phase I/IIa testing in heart failure patients. Using its expertise in lead optimization and computer aided drug design (CADD), Evotec has optimized a range of molecules with the aim of identifying clinical compounds.  The collaboration helped Cardioxyl Pharmaceuticals to move from the early stages of target validation to the initiation of clinical studies within 27 months.

"Our collaboration with Evotec has provided us with critical chemistry support during the development and optimization process of our lead compound, CXL-1020," said Cardioxyl's Chief Executive Officer, Chris Kroeger. "By accessing their proven skills in medicinal chemistry, CXL-1020 has entered the clinic on a timeline well ahead of the typical industry average"

Dr. Mario Polywka, Evotec's Chief Operating Officer commented, "This successful collaboration further validates our ability and expertise in advancing programmes through lead optimization and into the clinic. We are delighted that the significant efforts of Evotec and Cardioxyl have paid off with the progression of this project into the clinic so rapidly."

No financial details are disclosed. 

Forward-looking statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about our expectations and assumptions concerning regulatory, clinical and business strategies, the progress of our clinical development programs and timing of the results of our clinical trials, strategic collaborations and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that the Company may be unable to reduce its cash burn through recent restructuring and cost containment measures and may not recognize the results of such measures within the expected timeframe; risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of our collaborations, partnerships and acquisitions in the timeframes expected, or at all; risks relating to our ability to advance the development of product candidates currently in the pipeline or in clinical trials; our inability to further identify, develop and achieve commercial success for new products and technologies; the risk that competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; our failure to comply with regulations relating to our products and product candidates, including FDA requirements; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally.

The list of risks above is not exhaustive. Our most recent Annual Report on Form 20-F, filed with the Securities and Exchange Commission, and other documents filed with, or furnished to the Securities and Exchange Commission, contain additional factors that could impact our businesses and financial performance. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.